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Abstract
 
Lymphocyte homing to secondary lymphoid tissue is defined by a multistep sequence of inter-
actions between lymphocytes and endothelial cells in high endothelial venules (HEVs). After
initial selectin-mediated tethering and rolling, firm adhesion of lymphocytes requires rapid up-
regulation of lymphocyte integrin adhesiveness. This step is mediated in part by the HEV-
derived chemokine SLC (secondary lymphoid-tissue chemokine, or CCL21) that binds to the
CC chemokine receptor (CCR)7 on lymphocytes. However, the CC chemokine ELC (Epstein-
Barr virus–induced molecule 1 ligand chemokine, or CCL19) shares the same receptor, and
ELC transcripts have been observed in the T cell areas of lymphoid organs. Here, we show that
perivascular ELC is transcytosed to the luminal surfaces of HEVs and enables efficient T cell
homing to lymph nodes. In situ hybridization on sections of human tonsil showed no ELC
mRNA in HEVs, but immunostaining revealed ELC protein in cytoplasmic vesicles of HEV
cells. Furthermore, ELC injected into the footpads of mice entered the draining lymph nodes
and was presented by HEVs. Finally, intracutaneous injections of ELC in mice lacking func-
tionally relevant ELC and SLC
 
 
 
(
 
plt/plt
 
 mice) restored T cell trafficking to draining lymph nodes
as efficiently as SLC. We conclude that perivascular ELC is transcytosed to the luminal surfaces
of HEVs and participates in CCR7-mediated triggering of lymphocyte arrest.
Key words: chemokines • lymphocyte trafﬁcking • vascular endothelium • lymphoid tissue • 
 
plt/plt
 
 mice
 
Introduction
 
Continuous migration of lymphocytes from the peripheral
blood to organized lymphoid tissue and back to the circula-
tion is essential for immune surveillance and the generation
of immune responses. Lymphocyte emigration in periph-
eral lymphoid organs occurs through the walls of high en-
dothelial venules (HEVs) in a stepwise sequence of interac-
tions between lymphocytes and HEV cells (1–3). This
adhesion cascade is initiated by selectin-mediated rolling
but requires a subsequent signaling event that triggers rapid
integrin-mediated adhesion to the endothelium, and finally
diapedesis. Recently, several candidate chemotactic cyto-
kines (chemokines) with a potential to induce such lymph-
ocyte triggering under flow conditions have been identified
(4). These include chemokines constitutively expressed in
lymphoid tissue (and thus termed “lymphoid chemo-
kines”), such as SLC (secondary lymphoid-tissue chemo-
kine, also called 6Ckine, exodus 2, or TCA-4, and recently
designated CCL21) and ELC (Epstein-Barr virus–induced
molecule 1 ligand chemokine, also called macrophage in-
flammatory protein (MIP)-3
 
b
 
, exodus 3, or CCL19) (5–7).
SLC and its receptor, CCR7, are currently regarded as the
best candidates for chemokine-induced adhesion triggering
in HEVs. Thus, SLC is expressed by HEV endothelium in
normal mice (8–10) but is lacking in mice homozygous
for a spontaneous mutation, 
 
plt
 
 (paucity of lymph node
T cells), that have severe defects in T cell homing
(9–13). Furthermore, chemokine-induced desensitization
of CCR7 inhibits T cell adherence to HEVs in wild-type
mice (9, 10). Moreover, mice with targeted deletion of the
SLC receptor CCR7 have severe defects in lymphocyte
homing to peripheral lymphoid organs (14). On the other
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hand, a role for ELC in triggering of shear-resistant lymph-
ocyte adhesion to the HEV surface has been less obvious.
Although ELC shares with SLC the binding specificity to
CCR7, attracts the same major populations of lymphocytes
(15, 16), and has recently been shown to be deleted in 
 
plt/
plt
 
 mice as well (17, 18), ELC transcripts are restricted to
nonendothelial cells in the T cell zone of secondary lymphoid
organs (19, 20). However, abluminal internalization and
subsequent transcytosis of chemokines can apparently take
place in endothelial cells, because intradermally injected IL-8
(CXCL8) was shown to be transendothelially transported
and luminally posted in postcapillary venules (21). In this
manner, perivascular expression of chemokines may be re-
layed to circulating leukocytes.
Here we show that perivascular ELC is taken up by
HEV cells and translocated to their luminal surface mem-
branes. In situ mRNA hybridization performed on sections
of human tonsils demonstrated strong mRNA signals from
cells in the T cell zone, but no transcripts were detected in
HEVs. However, immunohistochemical staining revealed
ELC in cytoplasmic vesicles of HEV cells as well as in
perivascular cells. Furthermore, 
 
125
 
I–ELC injected into
footpads of mice entered draining lymph nodes and was
detected in HEV cells and in the HEV lumen. Finally, in-
tracutaneous injections of ELC in 
 
plt/plt
 
 mice restored T
cell homing to the draining lymph nodes. Altogether, our
data showed that ELC is likely to participate in CCR7-
mediated triggering of lymphocyte arrest in HEVs.
 
Materials and Methods
 
In Situ Hybridization.
 
A 434-bp, digoxigenin (DIG)-labeled
riboprobe was generated from the coding region of human ELC
with a DIG RNA labeling kit according to the manufacturer’s di-
rections (Boehringer Mannheim). All steps were performed at
room temperature unless otherwise noted. Frozen sections (8 
 
m
 
m)
from tissue specimens embedded in OCT (TissueTek) were fixed
in 4% paraformaldehyde/diethylpyrocarbonate (DEPC)-treated
PBS (15 min) and subsequently washed twice (15 min each) in
PBS containing 0.1% active DEPC (Sigma-Aldrich). After 15-min
equilibration in 5
 
3
 
 SSC, sections were prehybridized (2 h, 59
 
8
 
C)
in a solution of 50% formamide, 5
 
3
 
 SSC, 50 
 
m
 
g/ml yeast tRNA,
100 
 
m
 
g/ml heparin, 1
 
3
 
 Denhardt’s solution, 0.1% Tween 20,
0.1% CHAPS, and 5 mM EDTA. Sections were subsequently hy-
bridized overnight at 59
 
8
 
C with 500 ng/ml of riboprobe in hy-
bridization solution. A high stringency wash was performed in the
following sequence: 2
 
3
 
 SSC (30 min), 2
 
3
 
 SSC (1 h, 65
 
8
 
C), and
0.1
 
3
 
 SSC (1 h, 65
 
8
 
C). Sections were then equilibrated in buffer 1
(100 mM Tris-HCl, 150 mM NaCl, pH 7.5) for 15 min, incu-
bated (2 h) with alkaline phosphatase–conjugated sheep anti-DIG
(1:5,000; Boehringer Mannheim) and 0.5% Boehringer Blocking
Agent dissolved in buffer 1, and subsequently given a wash in two
changes of buffer 1 (15 min each). Sections were next equilibrated
in the substrate buffer (100 mM Tris-HCl, 150 mM NaCl, 50
mM MgCl
 
2
 
, pH 9.5) for 5 min, and finally developed overnight
in substrate buffer containing nitroblue tetrazolium chloride and
5-bromo-4-chloro-3-indolyl-phosphate (Boehringer Mannheim)
according to the manufacturer’s instructions.
 
Immunohistochemistry.
 
Immunostaining on cryosections (8
 
m
 
m) from surgical specimens of fresh palatine tonsils (
 
n
 
 
 
5
 
 4) and
Peyer’s patches (
 
n
 
 
 
5
 
 2) was performed as described (22). In brief,
acetone-fixed sections were first incubated with a mixture of
mAb MECA-79 (rat IgM, 1:30; courtesy of E.C. Butcher, Stan-
ford University Medical School, Stanford, CA) and MAB361
(mouse IgG2
 
b
 
, 0.3 
 
m
 
g/ml; R&D Systems) against human ELC,
followed by a mixture of Alexa Fluor 488 (Molecular Probes)
conjugated goat anti–mouse IgG2
 
b
 
 (1.5 
 
m
 
g/ml; Southern Bio-
technology Associates, Inc.) and Cy3-conjugated goat anti–rat Ig
(1:1,000; Jackson ImmunoResearch Laboratories). In another
protocol, mAb LS134 (mouse IgG1, 5 
 
m
 
g/ml; LeukoSite) or
AF361 (affinity-purified goat IgG, 5 
 
m
 
g/ml; R&D Systems)
against human ELC was followed by Cy3-conjugated goat anti–
mouse IgG1 (1:2,000; Southern Biotechnology Associates, Inc.)
or Alexa Fluor 488–conjugated donkey anti–goat IgG (1:1,000;
Molecular Probes), respectively. Negative controls were tissue
sections incubated with irrelevant isotype- and concentration-
matched mAbs.
 
Electron Microscopy.
 
Immunoelectron microscopy was per-
formed on sections of palatine tonsils (
 
n 
 
5
 
 3) as detailed else-
where (22). In brief, tissue specimens were prefixed in 1%
paraformaldehyde, and putative HEV-rich areas were cut into
rectangular strips (2 
 
3
 
 2 
 
3
 
 5 mm), followed by immersion in 1%
paraformaldehyde and 0.5% glutaraldehyde, dehydration in etha-
nol with progressive lowering of temperature to 
 
2
 
20
 
8
 
C, and em-
bedding in Unicryl (BioCell). Ultrathin sections were cut and
mounted on formvar-coated nickel grids (Agar Scientific).
Sections were incubated with affinity-purified goat antibodies
against human ELC (5 
 
m
 
g/ml; R&D Systems), followed by bio-
tinylated rabbit anti-goat (1:100; Zymed Laboratories) and finally
by 5-nm gold-conjugated streptavidin (1:40; Amersham Pharma-
cia Biotech). Sections were silver enhanced and contrasted with
uranyl acetate and lead citrate. Control sections were incubated
with concentration-matched normal goat IgG.
 
Autoradiography.
 
To obtain functional information, HEV-
rich tonsil specimens (5 
 
3
 
 5 
 
3 
 
5 mm) from two patients in sepa-
rate experiments (each in triplicate) were incubated for 60 or 120
min at 37
 
8
 
C in RPMI/0.1% BSA (Life Technologies) containing
2.2 nM/12.5 
 
m
 
Ci 
 
125
 
I–ELC (NEN Life Science Products). For
displacement binding experiments, 220 nM unlabeled ELC
(R&D Systems) was added. The specimens were then washed
three times for 5 min in PBS, fixed in 4% PFA at 4
 
8
 
C overnight,
and finally snap frozen in OCT. In another set of experiments,
2.5 or 9 ng of 
 
125
 
I–ELC (250 
 
m
 
Ci/
 
m
 
g) or 
 
125
 
I–MIP-1
 
a
 
 (275
 
m
 
Ci/
 
m
 
g) (both from NEN Life Science Products) in PBS was in-
jected into the hind and front footpads of 12-wk-old BALB/c
mice (three mice per chemokine). After 90 min, the draining and
contralateral popliteal and axillary lymph nodes were harvested
and processed for autoradiography as described for the tonsillar
specimens.
Cryosections (15 
 
m
 
m) of all tissue specimens were air dried
overnight, and the localization of bound radioactive chemokine
was revealed by autoradiography with Ilford K5 emulsion devel-
oped with D-19 developer (Eastman Kodak Co.) after 3–8 d of
exposure at 4
 
8
 
C.
 
Lymphocyte Homing Assays.
 
Donor T cells from mice express-
ing green fluorescent protein (GFP) under control of the murine
CD4 promoter and proximal enhancer (T–GFP) (23) were pre-
pared as described (9). In brief, lymph nodes were removed and
passed through a 70-
 
m
 
m sterile nylon mesh (Corning). The re-
sulting single-cell suspension was washed twice and resuspended
at 10
 
8
 
 cells/ml in HBSS containing 1% FCS and 15 mM Hepes.
Recipient 
 
plt/plt
 
 mice were anesthetized with ketamine/xylaxine
and received an intracutaneous injection of recombinant murine 
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(rm)SLC or rmELC (2.5 nmol; R&D Systems; two mice per
chemokine) unilaterally in the flank. The contralateral flank was
injected with vehicle (50 
 
m
 
l PBS). After 10 min, 5 
 
3
 
 10
 
7
 
 T–GFP
lymphocytes were injected via the tail vein, and the mice were
left to recover for 90 min. Thereafter, a blood sample was taken
and the mice were killed. The ipsilateral subiliac lymph node, as
well as the contralateral subiliac and brachial lymph nodes, were
removed and digested with collagenase type II (Worthington
Biochemical). The resulting single-cell suspension was analyzed
by flow cytometry (FACScan™; Becton Dickinson) to deter-
mine the percentage of GFP
 
1
 
 T cells in each sample. To deter-
mine the total number of lymphocytes homing to each lymph
node, a known number of PK26-labeled microspheres (Sigma-
Aldrich) was added to each sample. For comparison of recruited
T–GFP cells between the ipsilateral and contralateral lymph
nodes, the paired Student’s 
 
t
 
 test was used.
 
Results
 
ELC mRNA Is Expressed in the T Cell Zone of Human
Tonsils but Not in HEVs.
 
By means of mRNA hybridiza-
tion analysis in situ, we confirmed and extended the find-
ings reported by Dieu et al. (20) that ELC is expressed by
nonendothelial cells in the T cell zone of human tonsils.
Strikingly, the ELC antisense probe hybridized to spindle-
shaped cells in the T zone (Fig. 1 a), as well as to perivascu-
lar cells intimately associated with the HEV basement mem-
brane (Fig. 1 b), whereas no hybridization was observed in
endothelial cells. Also, we found no ELC transcripts in B
cell follicles or other areas outside the T cell zone. Hybrid-
ization with a sense probe gave no signal (not shown).
 
ELC Protein Is Found in Tonsillar HEVs and Perivascular
Cells.
 
Two-color immunofluorescence staining for ELC
(Fig. 1 c) revealed a prominent labeling of 50–90% (range
of four separate specimens) of MECA-79
 
1
 
 tonsil HEVs
(Fig. 1 d). Furthermore, ELC labeling was not restricted
to HEVs, as MECA-79
 
2
 
 vessels in the T cell zone also
contained chemokine (Fig. 1, c and d, arrowheads).
Figure 1. ELC protein is accumulated within HEVs, whereas ELC
transcripts are found perivascularly. In situ hybridization with an RNA
probe complementary to ELC mRNA. (a) Overview of tonsillar section
showing positive cells (black) confined to T cell areas. (b) Higher magnifi-
cation shows strong signals from perivascular cells partly surrounding the
HEV (border delineated), whereas endothelial cells are negative. Single
exposures of two-color immunofluorescence staining identifying ELC by
means of MAB361 (c and e) and HEVs by means of mAb MECA-79 (d, f,
and h). Most MECA791 HEVs contain ELC, whereas MECA-791ELC2
vessels are also seen (c and d, arrows). MECA-792ELC1 vessels are also
found in the T cell zone (c and d, arrowheads). (e) HEV-associated ELC
staining is distinctly luminal (arrowheads) and remarkably granular intra-
cellularly (arrows), in contrast to the MECA-79 antigen distribution (f).
Staining with an irrelevant control mAb (g) produces no signal together
with MECA-79 (h). Scale bars: b and e–h, 15 mm; c and d, 25 mm.
Figure 2. ELC protein is found in cytoplasmic vesicles of HEVs and at
the HEV–lymphocyte interface. Silver-enhanced immunogold staining
with goat anti–human ELC on sections of Unicryl-embedded tonsillar
tissue. (a) Electron micrograph of interface between an HEV cell and
lymphocyte shows vesicle-associated gold particles near the luminal
plasma membrane of endothelial cells (arrows and high magnification in-
sets). Note also membrane-proximal cytoplasmic vesicles of adjacent
lymphocyte (arrowheads). (b and c) ELC labeling in intracellular vesicles
(arrows and high magnification inset). Note absence of markers in the in-
terendothelial cleft (b, arrowheads). (d) Staining with irrelevant control
antibody. EC, endothelial cell; LC, lymphocyte; PC, pericyte. Scale bars:
a and d, 500 nm; b and c, 200 nm. 
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Higher magnification of MECA-79
 
1
 
 HEVs (Fig. 1 f) usu-
ally revealed a distinct luminal ELC staining as well as a
remarkably granular intracellular pattern (Fig. 1 e). No la-
beling was observed with an irrelevant mouse control
mAb (Fig. 1 g). Immunostaining for ELC with another
mAb, or with a goat polyclonal antibody, produced simi-
lar staining patterns (data not shown). Furthermore, im-
munostained sections of Peyer’s patches revealed ELC in
intestinal HEVs (data not shown). ELC
 
1 
 
granules were
not colocalized with von Willebrand factor, a marker for
regulated exocytosis in endothelial cells (data not shown).
 
ELC Is Present in Cytoplasmic Vesicles of HEV Cells and at
HEV–Lymphocyte Interfaces.
 
The subcellular localization
of ELC was studied by immunoelectron microscopy. In
this context, it should be emphasized that the tissue was
fixed by exposure to low concentration of aldehydes and
subsequent low-temperature Unicryl embedding, thus
omitting postfixation in osmium tetroxide and heat poly-
merization. By this procedure, antigenic epitopes were well
preserved, and fewer shrinkage artifacts were introduced,
but at the cost of less distinct subcellular membranes.
Therefore, intracellular vesicles could be identified prima-
rily by means of focally concentrated immunolabeling. In
sections of tonsillar tissue, we found distinct HEV-associ-
ated ELC labeling of intracellular vesicles in all parts of the
cytoplasm, including the luminal regions (Fig. 2, a–c, ar-
rows). These vesicles were of variable diameter and consis-
tent with vesicular transport. Notably, gold particles were
not observed in the interendothelial clefts (Fig. 2 b, arrow-
heads), thus making paracellular transport of ELC quite un-
likely. Furthermore, ELC was found in membrane-proxi-
mal vesicles of adjacent lymphocytes (Fig. 2 a, arrowheads),
probably reflecting receptor binding and subsequent inter-
nalization of the ligand–receptor complex (24). Sections
incubated with concentration-matched irrelevant goat IgG
showed no staining (Fig. 2 d).
 
HEVs Possess Binding Sites for ELC.
 
To test whether
HEV cells have a functional capacity for ELC binding in
situ, we prepared tonsillar tissue specimens for organ cul-
ture with addition of 
 
125
 
I–ELC and subsequent autoradiog-
raphy. We restricted our analysis to tissue areas 
 
z
 
1.5 mm
from the edges of the sections to avoid sampling errors due
to diffusion of the incubation medium. After 60 min of in-
cubation, radioactive signals were predominantly associated
with HEVs (Fig. 3 a) and their lumina (Fig. 3 b), whereas
the surrounding tissue was only weakly labeled. Notably,
flat-walled vessels of all calibers failed to emit signals above
background levels (Fig. 3 c and data not shown). This ar-
gues against general vascular perfusion and rapid filling of
 
125
 
I–ELC-containing buffer in larger lumen blood vessels
such as HEVs or that it is the meniscus of emulsion that
forms at the edge of tissue that gives rise to the grains. Ad-
dition of 100-fold excess of unlabeled ELC substantially re-
duced the radioactive signals (Fig. 3 d).
 
ELC Injected into Footpads of Mice Accumulates in HEVs of
Draining Lymph Nodes.
 
To directly assess whether HEV
cells have a functional capacity for basolateral ELC uptake
and luminal presentation in vivo, we determined the fate
of footpad-injected 
 
125
 
I–ELC in BALB/c mice by autora-
diography. After 90 min, injected ELC was readily detected
in afferent lymphatics (Fig. 4 a, arrow), as well as in the
subcapsular sinus (arrowheads) of draining popliteal and
axillary lymph nodes. As shown in Fig. 4, b–f, examination
of the lymph node stroma revealed ELC signals predomi-
nantly in lymphatic sinus of the paracortical T cell zone
(arrowheads) and associated with HEVs (arrows). Radiola-
beling was seen both inside HEV cells and on their luminal
surfaces. Injected MIP-1
 
a
 
 was also targeted to the subcap-
sular region of draining lymph nodes (not shown) but was
preferentially sequestered within the cortical B cell zone
and was not found in HEV cells of the T cell zone (Fig. 4
g). However, some HEVs near the follicular mantle zones
contained weak radiolabel (not shown). Endothelial cells in
contralateral lymph nodes from all animals contained no
radiolabel (Fig. 4 h and data not shown), ruling out sys-
temic delivery of chemokines in our experiments.
Figure 3. HEVs possess binding sites for ELC. Autora-
diography of tissue sections made after tonsillar organ cul-
ture with radioiodinated ELC. (a and b) Strong signals are
predominately associated with HEV cells and the HEV lu-
men. In contrast, flat-walled vessels (c) show no signal. (d)
Addition of excess cold ELC abolishes HEV-associated sig-
nals. Scale bars: 25 mm. 
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Figure 4. ELC injected into mice footpads is taken up by
HEVs and presented at their luminal surfaces. 125I–ELC in-
jected into BALB/c mice is detected by autoradiography in the
afferent lymphatics (a, arrow) as well as in the subcapsular sinus
(arrowheads) of draining lymph nodes after 90 min. In the T
zone, ELC signals are predominately found in the HEVs (b, ar-
row) and lymphatic sinus (arrowheads). Higher magnification
of areas outlined in c and e reveals radiolabel both inside HEV
cells and on their luminal surfaces (d and f, arrows), as well as in
the surrounding sinus (arrowheads). Injected 125I–MIP-1a is
preferentially sequestered within the B zone, but HEV cells in
the T zone are not labeled (g). Endothelial cells in contralateral
lymph nodes contain no radiolabel (ELC-injected mouse
shown in h). Scale bars: 25 mm.
 
Intracutaneously Injected ELC Reconstitutes T Cell Homing
to plt/plt Lymph Nodes.
 
To directly test whether ELC has
the capacity to mediate T cell homing to lymph nodes, 
 
plt/
plt
 
 mice received intracutaneous injections of either ELC
or SLC (2.5 nmol of each) unilaterally in the flank skin, fol-
lowed by intravenous transfer of fluorescent T cells (T–
GFP) (23). After 90 min, we found that significantly more
T–GFP cells homed to lymph nodes draining the ELC in-
jection site compared with the contralateral lymph nodes.
Furthermore, at the dose tested, intracutaneously injected
ELC recruited T–GFP cells to lymph nodes as efficiently as
SLC (Fig. 5 a). All mice had similar circulating level of
T–GFP cells (Fig. 5 b).
 
Discussion
 
A role for chemokines in lymphocyte adhesion triggering
has gained direct experimental support only recently (4, 9,
25). Solid evidence to this end comes from experiments in
 
plt/plt
 
 mice that have reduced numbers of T cells in periph-
eral lymph nodes (11) and lack SLC expressed in HEVs (9,
10, 12, 13). In fact, normal T cells injected into plt/plt mice
interact with HEVs by rolling at normal rates but fail to en-
gage in trigger-dependent adhesion (9, 10). Although data
generated in plt/plt mutants and normal mice suggest a cru-
cial role of SLC in the recruitment of T cells, the interpreta-
tion of these experiments is complicated by several issues.
First, novel data show that plt/plt mice not only lack SLC
but also ELC protein in their peripheral lymphoid organs.
The single functional ELC gene is deleted in these mice,
and the transcripts detected in previous studies stem from
one or more nonfunctional pseudogenes (17, 18). Hence,
plt/plt mice are deficient in both CCR7 ligands in their
lymphoid tissue. Second, CCR7 was desensitized by pre-
treatment with either SLC or ELC before injection, thereby
corroborating a role for CCR7 but not identifying the in-
volvement of either ligand alone. Third, despite a proposed
role for the elongated, basic COOH terminus of SLC in
enhanced tethering to proteoglycans in the HEV lumen (9),
other chemokines (IL-8 and RANTES (regulated upon ac-
tivation, normal T cell expressed and secreted)/CCL5; see
below) can also be presented at the luminal face of venules
(21), indicating that this elongation is not an absolute re-
quirement for luminal chemokine retention. Therefore, in
light of our study, ELC and SLC may be equally important
triggers of CCR7-mediated adhesion, and the dissection of1110 ELC Transcytosis in HEVs
their relative importance awaits future in vivo studies and
the use of blocking mAbs to either chemokine.
Our data demonstrate convincingly that ELC generated
in the perivascular interstitium was translocated by HEVs
to their luminal faces. Although transcription of ELC was
restricted to cells in the perivascular stroma, ELC protein
was found in cytoplasmic vesicles of HEV cells and associ-
ated with their surface membranes. ELC staining on tonsil-
lar HEVs has recently also been reported by others (24).
Furthermore, radiolabeled ELC added to our tonsillar or-
gan cultures was almost exclusively localized to HEVs, thus
showing that HEVs possess binding sites for ELC. This
might be constituted by the very prominent and acidic gly-
cocalyx found on HEV cells and endothelial cells of other
postcapillary venules (26), which could bind the basic
ELC. Moreover, lymph-borne ELC delivered to the ablu-
minal surfaces of HEVs was translocated and apparently
presented at the HEV lumen. Finally, exogenous ELC re-
stored T cell homing to plt/plt lymph nodes in vivo at least
as efficiently as SLC.
Taken together, our study lends strong support to the
proposed mechanism of abluminal-to-luminal transcytosis
of chemokines in postcapillary venules (21). Chemokine
transcytosis in HEV cells may not be restricted to ELC, be-
cause intradermally injected SLC is rapidly translocated to
the surfaces of HEVs in draining lymph nodes (9). Further-
more, mast cell–derived MIP-1b (CCL4) is known to be
presented within HEV in inflamed lymph nodes (27). Al-
though the molecular mechanism for chemokine uptake
and transcytosis in endothelial cells remains unclear, the
Duffy antigen/receptor of chemokines (DARC) has been
implicated in the endothelial binding and transcytosis of IL-8
and RANTES (21). Moreover, DARC is strongly and
quite specifically expressed by tonsillar HEV cells (22).
However, we were unable to detect affinity of ELC to two
different DARC transfectants in vitro (unpublished data)
and hypothesize that ELC might therefore utilize other
molecules with chemokine-binding properties. Possible
candidates could include sulfated glycosaminoglycans such
as heparan sulfate, which appears to be important for the
interaction of IL-8 with endothelial cells (21).
A mechanism for delivery of interstitial chemokines to
the abluminal surfaces of HEVs has been directly addressed
only recently (28). Small soluble molecules (including
chemokines) were shown to traverse the lymph node cor-
tex via the reticular network system of collagen fibers, a
protein meshwork extending from the subcapsular sinus to
ensheath the HEVs (29). Indeed, Gretz et al. (28) found
lymph borne MIP-1a (CCL3) localized to this reticular
network and around HEVs 5–30 min after footpad injec-
tions. Our observation of follicle-associated MIP-1a could
be explained by the fact that we sampled after 90 min. We
also found ELC labeling associated with collagen fibers in
the tonsillar stroma by immunoelectron microscopy, in a
pattern possibly corresponding to this conduit system (un-
published observations).
In conclusion, this study provides strong evidence that
ELC can be made available to rolling lymphocytes in HEVs
by specific endothelial uptake and transcytosis. Therefore,
we suggest that the relative importance of ELC versus SLC
should be reevaluated.
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